Cosmo Pharmaceuticals N.V., a leading biopharmaceutical company headquartered in Ireland (IE), focuses on developing innovative treatments for gastrointestinal diseases and other specialised areas. Founded in 1997, Cosmo has established a strong presence in Europe and the United States, with significant operational activities in these key markets. The company is renowned for its unique drug delivery technologies, particularly in the field of endoscopy and gastrointestinal health. Its flagship products, including the advanced bowel preparation agent and proprietary drug formulations, set Cosmo apart in the competitive pharmaceutical landscape. With a commitment to research and development, Cosmo Pharmaceuticals has achieved notable milestones, positioning itself as a trusted name in the biopharmaceutical industry.
How does Cosmo Pharmaceuticals N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cosmo Pharmaceuticals N.V.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cosmo Pharmaceuticals N.V., headquartered in Ireland (IE), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, there is no information available regarding their scope of emissions (Scope 1, 2, or 3) or any significant achievements in emissions reduction. The lack of data suggests that Cosmo Pharmaceuticals N.V. may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust climate commitments and transparency in emissions reporting. However, without specific data or commitments from Cosmo Pharmaceuticals N.V., it is challenging to assess their environmental impact or sustainability initiatives.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cosmo Pharmaceuticals N.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.